



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On August 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Kathryn A. Negriation

COPY OF PAPERS
ORIGINALLY FILED

#3

PATENT

Attorney Docket No.: 018484-002121US
Client Ref. No.: Pitt 04/02US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Christopher H. Evans, et al.

Application No.: 10/086,068

Filed: February 26, 2002

For: SYSTEMIC GENE TREATMENT
OF CONNECTIVE TISSUE DISEASES

Examiner: Not Yet Assigned

Art Unit: 1633

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE SPECIFICATION:

On page 17, paragraph [0069], line 12, delete the comma after "the". The comma after "the" has been deleted in the following corrected Paragraph [0069]:

[0069] Figure 1 shows a schematic representation of the provirus form of Moloney murine leukemia virus (MoMLV) that is used for the construction of retroviral vectors. The MFG retroviral vector is a simplified MoMVL retroviral vector in which the DNA sequences encoding the *pol* and *env* proteins have been deleted. A cDNA encoding human IRAP (Figure 2) was inserted into the NcoI and BamHI cloning sites of the